10月24日，Tango Therapeutics Inc.盘中下跌12.1%，报24.545美元，成交额2.53亿美元。
消息面上，公司公布vopimetostat与daraxonrasib联合疗法在既往治疗胰腺癌患者中的Ⅰ／Ⅱ期更新数据：22名可评估患者中客观缓解率82%，9个月无进展生存率88%，疾病控制率100%，中位无进展生存期尚未达到。
不过，安全性方面，40%的安全性可评估患者出现3级治疗相关不良反应；公司同时表示，计划于明年上半年启动针对MTAP缺失胰腺癌的一项全球随机Ⅲ期试验。数据虽积极，但早期试验属性与安全性指标令市场交易情绪出现分化。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.